Table 2 In-hospital care and complications among dying individuals with COVID-19 according to sex
| Â | Overall (n = 3517) | Women (n = 1171) | Men (n = 2346) | p value |
|---|---|---|---|---|
Symptoms at admission, n (%)a | ||||
 Fever | 2585 (76.3) | 795 (71.3) | 1790 (78.8) | < 0.001 |
 Shortness of breath | 2491 (73.6) | 794 (71.2) | 1697 (74.7) | 0.031 |
 Cough | 1315 (38.8) | 402 (36.1) | 913 (40.2) | 0.020 |
 Diarrhea | 193 (5.7) | 72 (6.5) | 121 (5.3) | 0.63 |
 Hemoptysis | 19 (0.6) | 5 (0.4) | 14 (0.6) | 0.18 |
Time (in days) from symptoms’ onset to; median [IQR]b | ||||
 Hospital admission | 4 [2–7] | 4 [2–7] | 5 [2–7] | < 0.001 |
 In-hospital nasopharyngeal swab | 5 [3–9] | 5 [2–9] | 6 [3–9] | 0.007 |
 ICU | 8 [5–12] | 7 [4–12] | 8 [5–12] | 0.12 |
 In-hospital death | 11 [7–17] | 11 [7–16] | 11 [7–17] | 0.06 |
Length of stay (days), median [IQR]c | 6 [3–11] | 6 [3–11] | 6 [3–11] | 0.80 |
Admission in ICUd | 667 (20.5) | 149 (13.9) | 518 (23.8) | < 0.001 |
In-hospital complicationse | ||||
 Acute respiratory distress syndrome | 3248 (96.9) | 1077 (96.4) | 2171 (97.2) | 0.24 |
 Acute renal injury | 741 (22.1) | 187 (16.7) | 554 (24.8) | < 0.001 |
 Acute cardiac injury | 368 (11.0) | 101 (9.0) | 267 (12.0) | 0.012 |
 Co-infection | 437 (13.0) | 136 (12.2) | 301 (13.5) | 0.30 |
Shock | 661 (19.7) | 168 (15.0) | 493 (22.1) | < 0.001 |
In-hospital treatments, n (%)f | ||||
 Antibiotics | 2908 (85.8) | 941 (84.3) | 1967 (86.5) | 0.08 |
 Antivirals (including hydroxychloroquine) | 2019 (59.6) | 583 (52.2) | 1436 (63.2) | < 0.001 |
 Steroids | 1293 (38.2) | 414 (37.1) | 879 (38.7) | 0.39 |
 Tocilizumab | 116 (3.9) | 15 (1.5) | 101 (5.1) | < 0.001 |